Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Purpose
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients with muscle invasive bladder cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a short period of time. Ultra-hypofractionated radiation therapy delivers radiation over an even shorter period of time than hypofractionated radiation therapy. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Chemotherapy drugs, such as mitomycin-C and 5-fluorouracil (5-FU), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ultra-hypofractionated radiation may be equally effective as hypofractionated therapy for patients with muscle invasive bladder cancer.
Conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Stage II Bladder Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Histologically proven, cT2-T3,N0M0 urothelial carcinoma of the bladder prior to
randomization.
- Note: Patients with mixed urothelial carcinoma will be eligible for the trial,
but the presence of small cell carcinoma will make a patient ineligible
- Must undergo a transurethral resection of bladder tumor (TURBT) prior to
randomization. Patients may have either completely or partially resected tumors as
long as the treating urologist attempted maximal resection
- Must undergo radiological staging prior to randomization. Imaging of chest, abdomen,
and pelvis must be performed using CT or MRI (with or without contrast is
acceptable). Patients must not have evidence of T4 or node positive disease.
Fluorodeoxyglucose (FDG) PET imaging is acceptable for radiological staging
- If any lymph nodes ≥ 1.0 cm in shortest cross-sectional diameter are noted on
imaging (CT / MRI of abdomen and pelvis), then the patient must have had a biopsy of
the enlarged lymph node showing no tumor involvement prior to randomization
- No diffuse carcinoma in situ (CIS) based on cystoscopy and biopsy
- No definitive clinical or radiologic evidence of metastatic disease
- Must not have had urothelial carcinoma or histological variant at any site outside
of the urinary bladder within 24 months prior to registration except Ta/T1/Carcinoma
in situ (CIS) of the upper urinary tract including renal pelvis and ureter if the
patient had undergone complete nephroureterectomy
- Age ≥ 18
- Zubrod performance status of ≤ 2
- Not pregnant and not nursing
- Negative urine or serum pregnancy test (in persons of childbearing potential)
within 14 days prior to registration. Childbearing potential is defined as any
person who has experienced menarche and who has not undergone surgical
sterilization (hysterectomy or bilateral oophorectomy) or who is not
postmenopausal
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3
- Platelets ≥ 100,000 cells/mm^3
- Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve
hemoglobin [Hgb]) ≥ 8.0 g/dl is acceptable)
- Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula
- Total bilirubin ≤ 2 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and
alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x
institutional ULN
- All adverse events associated with any prior therapy must have resolved to Common
Terminology Criteria for Adverse Events (CTCAE) grade ≤ 3 prior to randomization
- For patients who have completed neoadjuvant therapy, they are eligible if the
pre-neoadjuvant therapy diagnosis (TURBT path) is within 180 days before
randomization
- Must not have had prior pelvic radiation
- New York Heart Association Functional Classification II or better (NYHA Functional
Classification III/IV are not eligible) (Note: Patients with known history or
current symptoms of cardiac disease, or history of treatment with cardiotoxic
agents, should have a clinical risk assessment of cardiac function using the New
York Heart Association Functional Classification.)
- No active infection requiring IV antibiotics
- Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and
kidney function meet criteria specified
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm I (hypofractionated radiation therapy) |
Patients receive hypofractionated RT QD, Monday to Friday, for 20 treatments in the absence of disease progression or unacceptable toxicity. Patients also receive one of 3 systemic chemotherapy regimens per treating physician's choice: 1) cisplatin IV weekly for 4 weeks; 2) gemcitabine IV on days 1, 4, 8, 11, 15, 18, 22 and 25 or weekly for 4 weeks; or 3) mitomycin-C IV on day 1 and 5 FU, over 120 hours on days 1-5 and 22-26. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI or FDG PET throughout the study. In addition, patients may undergo optional blood and urine sample collection throughout the study, as well as an optional biopsy during cystoscopy during follow up. |
|
|
Experimental Arm II (Ultrahypofractionated radiation therapy) |
Patients receive ultra-hypofractionated RT QD, no more than twice weekly, for 5 treatments in the absence of disease progression or unacceptable toxicity. Patients also receive one of 3 systemic chemotherapy regimens per treating physician's choice: 1) cisplatin IV weekly for 4 weeks; 2) gemcitabine IV on days 1, 4, 8, 11, 15, 18, 22 and 25 or weekly for 4 weeks; or 3) mitomycin-C IV on day 1 and 5 FU, over 120 hours on days 1-5 and 22-26. Treatment given in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI or FDG PET throughout the study. In addition, patients may undergo optional blood and urine sample collection throughout the study, as well as an optional biopsy during cystoscopy during follow up. |
|
Recruiting Locations
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Irvine, California 92612
La Jolla, California 92093
Orange, California 92868
Sacramento, California 95817
Site Public Contact
916-734-3089
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Denver, Colorado 80206
Highlands Ranch, Colorado 80129
Site Public Contact
720-848-0650
Lone Tree, Colorado 80124
Lewes, Delaware 19958
Millville, Delaware 19967
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19718
Rehoboth Beach, Delaware 19971
Wilmington, Delaware 19801
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Doral, Florida 33166
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
786-596-2000
Miami, Florida 33176
Site Public Contact
305-243-2647
North Miami, Florida 33181
Plantation, Florida 33324
Site Public Contact
305-243-2647
Atlanta, Georgia 30303
Site Public Contact
404-778-1868
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Coeur d'Alene, Idaho 83814
Post Falls, Idaho 83854
Alton, Illinois 62002
Site Public Contact
618-463-5623
Bloomington, Illinois 61701
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Decatur, Illinois 62526
Decatur, Illinois 62526
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mount Vernon, Illinois 62864
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Oak Park, Illinois 60304
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Washington, Illinois 61571
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Clive, Iowa 50325
Site Public Contact
515-241-3305
Clive, Iowa 50325
Site Public Contact
515-241-3305
Creston, Iowa 50801
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Waukee, Iowa 50263
Site Public Contact
515-241-3305
West Des Moines, Iowa 50266
Site Public Contact
515-241-3305
West Des Moines, Iowa 50266
Site Public Contact
515-875-9815
Garden City, Kansas 67846
Kansas City, Kansas 66160
Overland Park, Kansas 66210
Pittsburg, Kansas 66762
Site Public Contact
888-446-3729
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Wichita, Kansas 67214
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Metairie, Louisiana 70002
Site Public Contact
504-584-6990
Boston, Massachusetts 02114
Site Public Contact
877-726-5130
Ann Arbor, Michigan 48109
Battle Creek, Michigan 49017
Brighton, Michigan 48116
Site Public Contact
800-865-1125
Brownstown, Michigan 48183
Clinton Township, Michigan 48038
Dearborn, Michigan 48126
Detroit, Michigan 48202
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Jackson, Michigan 49201
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49048
Site Public Contact
574-647-7370
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Novi, Michigan 48377
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
West Bloomfield, Michigan 48322
Wyoming, Michigan 49519
Burnsville, Minnesota 55337
Coon Rapids, Minnesota 55433
Edina, Minnesota 55435
Maple Grove, Minnesota 55369
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Monticello, Minnesota 55362
Robbinsdale, Minnesota 55422
Saint Cloud, Minnesota 56303
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Shakopee, Minnesota 55379
Stillwater, Minnesota 55082
Waconia, Minnesota 55387
Willmar, Minnesota 56201
Woodbury, Minnesota 55125
Bolivar, Missouri 65613
Cape Girardeau, Missouri 63703
Site Public Contact
888-446-3729
Cape Girardeau, Missouri 63703
Columbia, Missouri 65212
Site Public Contact
573-882-7440
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Joplin, Missouri 64804
Joplin, Missouri 64804
Kansas City, Missouri 64116
Site Public Contact
913-588-3671
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Osage Beach, Missouri 65065
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Rolla, Missouri 65401
Saint Joseph, Missouri 64506
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
St Louis, Missouri 63128
St Louis, Missouri 63131
Site Public Contact
314-996-5569
St Louis, Missouri 63141
Site Public Contact
314-251-7066
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Great Falls, Montana 59405
Havre, Montana 59501
Kalispell, Montana 59901
Missoula, Montana 59804
Lebanon, New Hampshire 03756
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
Commack, New York 11725
Site Public Contact
212-639-7592
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10065
Site Public Contact
212-639-7592
Uniondale, New York 11553
Site Public Contact
212-639-7592
Chapel Hill, North Carolina 27599
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Avon, Ohio 44011
Site Public Contact
800-641-2422
Beachwood, Ohio 44122
Cleveland, Ohio 44106
Columbus, Ohio 43210
Mentor, Ohio 44060
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Chadds Ford, Pennsylvania 19317
Charleston, South Carolina 29425
Gaffney, South Carolina 29341
Greenwood, South Carolina 29646
Greer, South Carolina 29651
Spartanburg, South Carolina 29303
Union, South Carolina 29379
Nashville, Tennessee 37204
Site Public Contact
800-811-8480
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Conroe, Texas 77384
Dallas, Texas 75235
Dallas, Texas 75390
Houston, Texas 77030
Houston, Texas 77079
League City, Texas 77573
Sugar Land, Texas 77478
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23226
Richmond, Virginia 23230
Antigo, Wisconsin 54409
New Richmond, Wisconsin 54017
Rhinelander, Wisconsin 54501
Stevens Point, Wisconsin 54481
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
Cheyenne, Wyoming 82001
More Details
- Status
- Recruiting
- Sponsor
- NRG Oncology
Study Contact
Detailed Description
PRIMARY OBJECTIVE: I. Demonstrate non-inferiority of ultra-hypofractionated (stereotactic body radiation therapy [SBRT]) compared to hypofractionated radiation therapy (RT) with a 10% non-inferiority margin (from 50% to 40%) in the rate of bladder-intact event-free survival (BI-EFS) at 3 years (corresponding to a hazard ratio < 1.32). SECONDARY OBJECTIVES: I. Compare the rates of urinary and bowel toxicity, patient-reported outcomes (PRO), event-free survival (EFS), metastasis-free survival (MFS), and overall survival (OS) between the two treatment arms. II. Compare and evaluate symptomatic adverse events and quality of life measures that are most meaningful to patients. III. Evaluate circulating tumor deoxyribonucleic acid (ctDNA) as a biomarker to determine whether it is predictive of disease recurrence and as a secondary outcome variable. EXPLORATORY OBJECTIVES: I. Evaluate ctDNA, tissue-free minimal residual disease (tfMRD) and urine tumor DNA (utDNA) as biomarkers for predicting recurrence. II. Evaluate tfMRD, obtained at the time of progression, to determine if it captures the presence of disease. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive hypofractionated radiation therapy (RT) once daily (QD), Monday to Friday, for 20 treatments in the absence of disease progression or unacceptable toxicity. Patients also receive one of 3 systemic chemotherapy regimens per treating physician's choice: 1) cisplatin intravenously (IV) weekly for 4 weeks; 2) gemcitabine IV on days 1, 4, 8, 11, 15, 18, 22 and 25 or weekly for 4 weeks; or 3) mitomycin-C IV on day 1 and fluorouracil (5 FU), over 120 hours on days 1-5 and 22-26. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) or fluorodeoxyglucose (FDG) positron emission tomography (PET) throughout the study. In addition, patients may undergo optional blood and urine sample collection throughout the study, as well as an optional biopsy during cystoscopy during follow up. ARM II: Patients receive ultra-hypofractionated RT QD, no more than twice weekly, for 5 treatments in the absence of disease progression or unacceptable toxicity. Patients also receive one of 3 systemic chemotherapy regimens per treating physician's choice: 1) cisplatin IV weekly for 4 weeks; 2) gemcitabine IV on days 1, 4, 8, 11, 15, 18, 22 and 25 or weekly for 4 weeks; or 3) mitomycin-C IV on day 1 and 5 FU, over 120 hours on days 1-5 and 22-26. Treatment given in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI or FDG PET throughout the study. In addition, patients may undergo optional blood and urine sample collection throughout the study, as well as an optional biopsy during cystoscopy during follow up. After completion of study treatment, patients are followed up at week 16, every 3 months for 3 years then every 6 months to year 5.